阿托伐他汀联合曲美他嗪治疗冠心病的疗效研究

目的：探讨阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效。方法选取2012年11月—2013年10月我院收治的冠心病住院患者183例，按照治疗方案和性别将所有患者分为阿托伐他汀组、曲美他嗪组和联合治疗组，每组61例。3组患者入院后均给予常规治疗，阿托伐他汀组患者加用阿托伐他汀，曲美他嗪组患者加用曲美他嗪，联合治疗组患者加用阿托伐他汀联合曲美他嗪；3组患者均连续治疗2周为1个疗程。观察3组患者治疗前后血脂、心绞痛发作次数、每次心绞痛发作持续时间及治疗后心功能、治疗期间不良反应情况。结果3组患者治疗前总胆固醇（ TC）、三酰甘油（ TG）、高密度脂蛋白胆固醇（ HDL－C）、低密度脂蛋白胆固醇（ LDL－C）及心绞痛发作次数、每次心绞痛发作持续时间比较，差异均无统计学意义（ P＞0.05）。联合治疗组患者治疗后TC、 TG及LDL－C低于阿托伐他汀组和曲美他嗪组， HDL－C高于阿托伐他汀组和曲美他嗪组（ P＜0.05）；心绞痛发作次数少于阿托伐他汀组和曲美他嗪组，每次心绞痛发作持续时间短于阿托伐他汀组和曲美他嗪组（ P＜0.05）；左室舒张末期内径（ LVEDD）、左室收缩末期内径（LVESD）小于阿托伐他汀组和曲美他嗪组，左室射血分数（LVEF）大于阿托伐他汀组和曲美他嗪组（P＜0.05）。联合治疗组患者治疗期间不良反应发生率低于阿托伐他汀组和曲美他嗪组（P＜0.05）。结论阿托伐他汀联合曲美他嗪治疗冠心病安全有效，有利于提高患者降脂效果、改善患者心功能。

Effect of Atorvastatin Combined with Trimetazidine on Coronary Heart Disease

Objective To investigate the clinical effect of atorvastatin combined with trimetazidine on coronary heart disease.Methods From November 2012 to October 2013, 183 patients with coronary heart disease were selected , and they were divided into groups A , B, C according to treatment protocols and gender , each of 61 cases.The three groups all given reg-ular treatment, and A group given extra atorvastatin , B group given extra trimetazidine , C group given extra atorvastatin and tri-metazidine.The three groups all treated for 2 weeks.Blood liquid, angina pectoris attacks frequencies , lasting time of every an-gina pectoris attack before and after treatment , heart function after treatment and incidence of adverse reactions during treatment of the three groups were observed . Results There was no significant differences of total cholesterol （ TC ） , triacylglycerol （TG）, high density lipoprotein cholesterol （HDL-C）, low density lipoprotein cholesterin （LDL-C）, angina pectoris at-tacks frequencies and lasting time of every angina pectoris attack in the three groups before treatment （ P〉0.05 ） .After treat-ment, TC, TG and LDL-C of C group were lower than those of groups A and B , and HDL-C was higher, angina pectoris at-tacks frequencies was less , lasting time of every angina pectoris attack was shorter （ P〈0.05）; left ventricular end diastolic di-ameter （LVEDD） and left ventricular end systolic diameter （LVESD） of C group were lower than those of groups A and B , and left ventricular ejection fraction （LVEF） was higher （P〈0.05）.The incidence of adverse reactions during treatment of C group was lower than that of groups A and B （ P〈0.05） .Conclusion Atorvastatin combined with trimetazidine is effective and safe in treating coronary heart disease , which is helpful to improve lipid -lowering effect and heart function .